(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | 93957-54-1

• 物质功能分类: 原料药 - 循环系统用药 - 调节血脂药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
• 英文别名: (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
• CAS: 93957-54-1；93957-55-2
• 化学式: C₂₄H₂₆FNO₄
• 分子量: 411.5
• InChiKey: FJLGEFLZQAZZCD-VAWYXSNFSA-N

物化性质

• 熔点：
  193.9-196.9 °C
• 沸点：
  681.8±55.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)
• 溶解度：
  水 25 mg/ml DMSO 100 mg/ml 乙醇 25 mg/ml
• 蒸汽压力：
  1.91X10-16 mm Hg at 25 °C (est)
• 稳定性/保质期：
  Stable under recommended storage conditions. /Fluvastatin sodium hydrate/
• 分解：
  Hazardous decomposition products formed under fire conditions - Carbon oxides, nitrogen oxides (NOx), hydrogen fluoride, sodium oxides. /Fluvastatin sodium hydrate/
• 解离常数：
  pKa = 4.5 (carboxy) (est)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  82.7
• 氢给体数：
  3
• 氢受体数：
  5

ADMET

代谢

体外数据表明，氟伐他汀的代谢涉及多种细胞色素P450（CYP）同工酶。CYP2C9同工酶主要参与氟伐他汀的代谢（约75%），而CYP2C8和CYP3A4同工酶的参与程度要低得多，即分别约占5%和约20%。

In vitro data indicate that fluvastatin metabolism involves multiple Cytochrome P450 (CYP) isozymes. CYP2C9 isoenzyme is primarily involved in the metabolism of fluvastatin (approximately 75%), while CYP2C8 and CYP3A4 isoenzymes are involved to a much less extent, i.e., approximately 5% and approximately 20%, respectively.

来源:Hazardous Substances Data Bank (HSDB)

代谢

氟伐他汀在肝脏中被代谢，主要是通过吲哚环在5和6位置的羟基化。N-脱烷基化和侧链的β-氧化也有发生。羟基代谢物具有一定的药理活性，但不会在血液中循环。氟伐他汀有两种对映异构体。氟伐他汀的两种对映异构体以类似的方式被代谢。

Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5 and 6 positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Fluvastatin has two enantiomers. Both enantiomers of fluvastatin are metabolized in a similar manner.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 毒性总结

识别和使用：氟伐他汀是一种抗胆固醇药物和羟甲戊二酸辅酶A还原酶抑制剂。人类暴露和毒性：已经报道了氟伐他汀胶囊和其他同类药物导致的横纹肌溶解伴急性肾功能衰竭。在接受他汀类药物，包括氟伐他汀治疗的患者中，有罕见报告肝衰竭的致命和非致命病例。如果在氟伐他汀治疗期间出现严重肝损伤、临床症状和/或高胆红素血症或黄疸，请立即中断治疗。氟伐他汀胶囊禁用于可能怀孕或已经怀孕的妇女。在正常怀孕期间，血清胆固醇和甘油三酯水平会升高，胆固醇或胆固醇衍生物对胎儿发育至关重要。氟伐他汀胶囊在孕妇中使用可能会对胎儿造成伤害。药物不良反应报告已经证实了与他汀类治疗相关的神经精神反应的发生。这些反应包括行为改变；认知和记忆损害；睡眠障碍；和性功能障碍。动物研究：在小鼠中以0.3、15和30 mg/kg/天的剂量进行的致癌性研究中发现，在30 mg/kg/天的雄性和雌性以及15 mg/kg/天的雌性中，食道鳞状细胞乳头状瘤有统计学显著增加，与大鼠中的情况相似。氟伐他汀在大鼠中以12 mg/kg/天的剂量和家兔中以10 mg/kg/天的剂量导致骨骼发育延迟。在以下研究中，无论有无代谢活化，均未观察到突变性：使用突变型沙门氏菌或大肠杆菌的微生物突变试验；BALB/3T3细胞的恶性转化试验；大鼠原代肝细胞的非计划性DNA合成；V79中国仓鼠细胞的染色体畸变；HGPRT V79中国仓鼠细胞。此外，在大鼠或小鼠微核试验中也没有观察到体内的突变性。

IDENTIFICATION AND USE: Fluvastatin is anticholesteremic agent and hydroxymethylglutaryl-CoA reductase inhibitor. HUMAN EXPOSURE AND TOXICITY: Rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with fluvastatin capsules and other drugs in this class. There have been rare reports of fatal and non-fatal hepatic failure in patients taking statins, including fluvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with fluvastatin, promptly interrupt therapy. Fluvastatin capsules are contraindicated in women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Fluvastatin capsules may cause fetal harm when administered to pregnant women. Adverse drug reaction reports have demonstrated the occurrence of neuropsychiatric reactions associated with statin treatment. They include behavioral alterations; cognitive and memory impairments; sleep disturbance; and sexual dysfunction. ANIMAL STUDIES: The carcinogenicity study conducted in mice at dose levels of 0.3, 15 and 30 mg/kg/day revealed, as in rats, a statistically significant increase in forestomach squamous cell papillomas in males and females at 30 mg/kg/day and in females at 15 mg/kg/day. Fluvastatin produced delays in skeletal development in rats at doses of 12 mg/kg/day and in rabbits at doses of 10 mg/kg/day. No evidence of mutagenicity was observed in vitro, with or without metabolic activation, in the following studies: microbial mutagen tests using mutant strains of Salmonella typhimurium or Escherichia coli; malignant transformation assay in BALB/3T3 cells; unscheduled DNA synthesis in rat primary hepatocytes; chromosomal aberrations in V79 Chinese Hamster cells; HGPRT V79 Chinese Hamster cells. In addition, there was no evidence of mutagenicity in vivo in either a rat or mouse micronucleus test.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 肝毒性

氟伐他汀治疗与1%至5%的患者出现轻度、无症状且通常是暂时的血清转氨酶升高有关，但在超过3倍ULN的水平上大约为1%。在大规模前瞻性监测研究的总结分析中，ALT升高超过正常范围的患者高达5%；氟伐他汀治疗组的ALT水平超过正常上限3倍（ULN）的发生率为1.1%，而安慰剂接受者为0.3%。这些升高在高剂量氟伐他汀时更为常见。大多数这些升高是自限性的，不需要调整剂量。氟伐他汀是最常与血清转氨酶升高相关联的statin类药物，也是与症状性肝损伤最高发生率相关的药物，然而，氟伐他汀引起的明显、临床上可见的肝损伤仍然相当罕见，估计在使用过程中每10,000人年发生1.7例。在报告的少数病例中，临床损伤的发作时间在1到4个月之内，损伤模式通常为胆汁淤积性或混合性。皮疹、发热和嗜酸性粒细胞增多不常见。至少有一例具有自身免疫特征的病例已被描述。大多数病例在发病后几个月内解决。极少数急性肝衰竭和死亡病例被归因于氟伐他汀。

Fluvastatin therapy is associated with mild, asymptomatic and usually transient serum aminotransferase elevations in 1% to 5% of patients but in levels above 3 times ULN is approximately 1%. In summary analyses of large scale studies with prospective monitoring, ALT elevations above normal occurred in up to 5% of patients; ALT levels of above 3 times the upper limit of normal (ULN) occurred in 1.1% of fluvastatin treated versus 0.3% of placebo recipients. These elevations were more common with higher doses of fluvastatin. Most of these elevations were self-limited and did not require dose modification. Fluvastatin is the statin most commonly associated with serum aminotransferase elevations and the highest rates of symptomatic liver injury, yet frank, clinically apparent hepatic injury from fluvastatin is still quite rare estimated to occur in 1.7 per 10,000 person years of use. In the few cases that have been reported, the onset of clinical injury has been within 1 to 4 months, the pattern of injury is typically cholestatic or mixed. Rash, fever and eosinophilia are uncommon. At least one case with features of autoimmunity has been described. Most cases resolve within a few months of onset. Rare cases of acute liver failure and death have been attributed to fluvastatin.

来源:LiverTox

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：目前没有关于在母乳喂养期间使用氟伐他汀的相关已发布信息。由于担心会干扰婴儿的脂质代谢，共识认为在母乳喂养期间不应使用氟伐他汀。然而，也有人认为对于家族性高胆固醇血症的同型纯合子儿童，从1岁开始就使用他汀类药物，他汀类药物的口服生物利用度较低，对哺乳婴儿的风险很低，尤其是罗苏伐他汀和普伐他汀。[1] 在有更多数据可用之前，可能会优先选择其他药物，特别是在哺乳新生儿或早产儿时。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No relevant published information exists on the use of fluvastatin during breastfeeding. Because of a concern with disruption of infant lipid metabolism, the consensus is that fluvastatin should not be used during breastfeeding. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with rosuvastatin and pravastatin.[1] Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

毒理性

• 相互作用

肌病病例，包括横纹肌溶解症，在使用氟伐他汀与秋水仙碱联合治疗时已有报道，因此在开具氟伐他汀与秋水仙碱联合处方时应谨慎。

Cases of myopathy, including rhabdomyolysis, have been reported with fluvastatin coadministered with colchicine, and caution should be exercised when prescribing fluvastatin with colchicine.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

在使用香豆素类抗凝剂的同时服用其他HMG-CoA还原酶抑制剂的患者中，已经报道了出血和/或凝血酶原时间增加的情况。因此，当开始使用氟伐他汀钠或更改氟伐他汀钠剂量时，接受华法林型抗凝剂治疗的患者应密切监测其凝血酶原时间。

Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors. Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

基于动物数据，氟伐他汀在母乳中的比例约为2:1（母乳：血浆）。

/MILK/ Based on animal data, fluvastatin is present in breast milk in a 2:1 ratio (milk:plasma).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

服用胶囊后，氟伐他汀在不到1小时内达到峰值浓度。服用10毫克剂量后的绝对生物利用度为24%（范围9%至50%）。

Following oral administration of the capsule, fluvastatin reaches peak concentrations in less than 1 hour. The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

氟伐他汀与血浆蛋白的结合率为98%。平均分布容积（VDss）估计为0.35 L/kg。在治疗浓度下，华法林、水杨酸和格列本脲不会影响氟伐他汀的蛋白结合。

Fluvastatin is 98% bound to plasma proteins. The mean volume of distribution (VDss) is estimated at 0.35 L/kg. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

氟伐他汀以氟伐他汀钠缓释片80毫克的形式给药，在空腹条件下、低脂餐后或低脂餐后2.5小时达到峰值浓度大约需要3小时。缓释片的平均相对生物利用度约为29%（范围：9%至66%），与空腹条件下给药的氟伐他汀即释胶囊相比。高脂餐后给药会延迟吸收（Tmax：6小时）并使缓释片的生物利用度提高约50%。然而，高脂餐后氟伐他汀钠缓释片达到的最大浓度低于单次剂量或每日两次剂量40毫克氟伐他汀胶囊后的峰值浓度。

Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal. The mean relative bioavailability of the extended-release tablet is approximately 29% (range: 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions. Administration of a high fat meal delayed the absorption (Tmax: 6 hr) and increased the bioavailability of the extended-release tablet by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  Xi
• WGK Germany：
  3
• 危险类别：
  3
• 安全说明：
  S23,S26,S37
• 危险类别码：
  R36/37/38,R42/43
• 包装等级：
  III
• 危险品运输编号：
  UN 3272 3/PG 3

制备方法与用途

降胆固醇药物：氟伐他汀 氟伐他汀简介

氟伐他汀（fluvastatin）是第一个全化学合成的降胆固醇药物，属于羟甲戊二酰辅酶A (HMG-CoA) 还原酶抑制剂。它通过将HMG-CoA转化为3-甲基-3, 5-二羟戊酸来发挥作用。

与洛伐他汀、新伐他汀和普伐他汀等已上市的天然或半合成HMG-CoA还原酶抑制剂相比，氟伐他汀具有结构相对简单、作用选择性高及不良反应发生率低的优点。因此，它是一种优秀的降血脂药。

药代动力学 吸收

健康志愿者空腹服用氟伐汀钠后，吸收迅速且完全（98%）。餐后服用会减慢其吸收速度。在服20 mg或40 mg氟伐汀钠胶囊1小时后，血浆峰浓度分别约为140 ng/mL和365 ng/mL。

分布

表观分布容积(Vz/f) 为330 L。超过98%的循环药物与血浆蛋白结合，且这种结合不受血药浓度的影响。

代谢

氟伐他汀主要通过β氧化、吲哚环5、6位的羟化和1位异丙基的丢失途径进行体内代谢。在人肝微粒体中，它主要被细胞色素P450同功酶CYP2C9亚族代谢。

药物相互作用

1. 消胆胺能增强氟伐他汀降胆固醇效能。
2. 与西咪替丁、雷尼替丁或奥美拉唑同用，可使本品血浓度升高，清除率下降。
3. 与利福平同用则降低本品血药浓度，增加清除率。
4. 与地高辛合用，可使地高辛血浓度升高。

作用和用途

氟伐他汀为人工合成品，化学结构类似普伐他汀。它通过抑制HMG-CoA还原酶和其他途径降胆固醇，在用药后4周达到最大疗效，继续用药疗效稳定。

适应症

用于动物脂肪和胆固醇饮食所致的高胆固醇血症（Ⅱa和Ⅱb）的治疗。

合成路线

氟伐他汀的活性成分为氟伐他汀钠。其合成路线如下：

参考资料：李玉龙, 刘菊. 氟伐他汀钠的合成工艺研究[J], 药物资讯, 20XX, X(X): XX-XX。

注意事项

1. 尽管氟伐他汀仅小部分药物经CYP3A4代谢，但应慎用。
2. 监测病人使用本品时出现的肌肉痛、触痛及突然衰弱，并注意不适和发热症状。如发现肌酐磷酸激酶（CPK）水平升高或肌痛即停止给药。
3. 在活动型肝炎、重症肝炎、孕妇、哺乳期妇女中禁用。与树脂类药物合用时，需间隔4小时避免降低生物利用度。
4. 给药前曾用过利福平的患者，将降低氟伐他汀的生物利用度50%。
5. 肝功能不正常者禁用。给药前或期间必须进行肝功测定。
6. 消胆胺可加强本品的药理活性。
7. 西咪替丁、雷尼替丁、奥美拉唑使本品Gmax 和AUC显著升高，血浆清除率下降。
8. 氟伐他汀与利福平同时使用则降低血药浓度，清除率升高。
9. 本品使地高辛Gmax升高，给药时应注意监护。

反应信息

• 作为反应物：
  描述：

  (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid 、 (3R,5S)-氟伐他汀钠盐 以Fluvastatin sodium (5.83 g), which was isolated from Lescol® capsules (commercially available from Novartis Pharmaceuticals, East Hanover, N.J的产率得到fluvastatin sodium
  参考文献：
  名称：

  Store operated calcium influx inhibitors and methods of use

  摘要：

  本发明提供了存储操作钙离子内流抑制剂化合物、制药组合物和使用方法。这些化合物可用于治疗炎症性疾病或炎症反应。优选地，本发明的化合物、组合物和方法可用于治疗炎症性皮肤、肺部、肌肉骨骼和胃肠疾病，以及自身免疫性疾病、移植治疗和骨质疏松症。

  公开号：

  US20030114353A1
• 作为产物：
  描述：

  fluvastatin sodium 、 β-环糊精 在 山梨醇 、 Stearic acid magnesium salt 、 fluvastatin sodium 作用下， 以 水 为溶剂， 生成 (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
  参考文献：
  名称：

  Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor

  摘要：

  本发明涉及一种含有HMG-CoA还原酶抑制剂的药物组合物，该组合物利用包合复合物剂保护其在酸性环境中的不稳定性，并进一步涉及其制备和用于治疗高胆固醇血症和高脂血症的用途。

  公开号：

  US20060229277A1

文献信息

• DISUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160221965A1

  公开（公告）日：2016-08-04

  The present application relates to novel 2,5-disubstituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

  本申请涉及新颖的2,5-二取代6-(三氟甲基)嘧啶-4(3H)-酮衍生物，其制备方法，其单独或与其他药物联合用于治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管、肾脏、炎症和纤维化疾病。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASES À CYSTÉINE DE TYPE CATHEPSINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015054038A1

  公开（公告）日：2015-04-16

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• [EN] SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] COMPOSÉS DE SULFONYLE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013123444A1

  公开（公告）日：2013-08-22

  The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的磺酰基化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
  申请人：Ryono Denis E.

  公开号：US20080009465A1

  公开（公告）日：2008-01-10

  Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

  提供了磷酸酯和磷酸酯激活剂，因此在治疗糖尿病和相关疾病方面非常有用，并具有以下结构： 其中 是杂环芳基环； R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ； R 5 和R 6 分别选择自H、烷基和卤素； Y为R 7 (CH 2 ) s 或不存在；以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义；或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
• New Drug Delivery System for Crossing the Blood Brain Barrier
  申请人：Lipshutz H. Bruce

  公开号：US20070203080A1

  公开（公告）日：2007-08-30

  New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.

  新的泛醌类似物被披露，以及利用这些化合物将药物基团输送到人体的方法。